Literature DB >> 22064714

A protective epitope in type III effector YopE is a major CD8 T cell antigen during primary infection with Yersinia pseudotuberculosis.

Yue Zhang1, Patricio Mena, Galina Romanov, Jr-Shiuan Lin, Stephen T Smiley, James B Bliska.   

Abstract

Virulence in human-pathogenic Yersinia species is associated with a plasmid-encoded type III secretion system that translocates a set of Yop effector proteins into host cells. One effector, YopE, functions as a Rho GTPase-activating protein (GAP). In addition to acting as a virulence factor, YopE can function as a protective antigen. C57BL/6 mice infected with attenuated Yersinia pestis generate a dominant H2-Kb-restricted CD8 T cell response to an epitope in the N-terminal domain of YopE (YopE69-77), and intranasal vaccination with the YopE69-77 peptide and the mucosal adjuvant cholera toxin (CT) elicits CD8 T cells that are protective against lethal pulmonary challenge with Y. pestis. Because YopE69-77 is conserved in many Yersinia strains, we sought to determine if YopE is a protective antigen for Yersinia pseudotuberculosis and if primary infection with this enteric pathogen elicits a CD8 T cell response to this epitope. Intranasal immunization with the YopE69-77 peptide and CT elicited a CD8 T cell response that was protective against lethal intragastric Y. pseudotuberculosis challenge. The YopE69-77 epitope was a major antigen (∼30% of splenic CD8 T cells were specific for this peptide at the peak of the response) during primary infection with Y. pseudotuberculosis, as shown by flow cytometry tetramer staining. Results of infections with Y. pseudotuberculosis expressing catalytically inactive YopE demonstrated that GAP activity is dispensable for a CD8 T cell response to YopE69-77. Determining the features of YopE that are important for this response will lead to a better understanding of how protective CD8 T cell immunity is generated against Yersinia and other pathogens with type III secretion systems.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22064714      PMCID: PMC3255672          DOI: 10.1128/IAI.05971-11

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  67 in total

1.  The RhoGAP activity of the Yersinia pseudotuberculosis cytotoxin YopE is required for antiphagocytic function and virulence.

Authors:  D S Black; J B Bliska
Journal:  Mol Microbiol       Date:  2000-08       Impact factor: 3.501

Review 2.  The type III secretion system tip complex and translocon.

Authors:  C A Mueller; P Broz; G R Cornelis
Journal:  Mol Microbiol       Date:  2008-04-08       Impact factor: 3.501

3.  Protection against Yersinia infection induced by non-virulence-plasmid-encoded antigens.

Authors:  M Simonet; P Berche; D Mazigh; M Veron
Journal:  J Med Microbiol       Date:  1985-10       Impact factor: 2.472

4.  Delineation of regions of the Yersinia YopM protein required for interaction with the RSK1 and PRK2 host kinases and their requirement for interleukin-10 production and virulence.

Authors:  Joseph B McPhee; Patricio Mena; James B Bliska
Journal:  Infect Immun       Date:  2010-06-01       Impact factor: 3.441

Review 5.  The virulence plasmid of Yersinia, an antihost genome.

Authors:  G R Cornelis; A Boland; A P Boyd; C Geuijen; M Iriarte; C Neyt; M P Sory; I Stainier
Journal:  Microbiol Mol Biol Rev       Date:  1998-12       Impact factor: 11.056

6.  Attenuated Yersinia pseudotuberculosis carrier vaccine for simultaneous antigen-specific CD4 and CD8 T-cell induction.

Authors:  Holger Rüssmann; Ulrike Gerdemann; Emeka I Igwe; Klaus Panthel; Jürgen Heesemann; Sara Garbom; Hans Wolf-Watz; Gernot Geginat
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

7.  Oral vaccination against bubonic plague using a live avirulent Yersinia pseudotuberculosis strain.

Authors:  Thierry Blisnick; Patrick Ave; Michel Huerre; Elisabeth Carniel; Christian E Demeure
Journal:  Infect Immun       Date:  2008-05-27       Impact factor: 3.441

Review 8.  Yersinia enterocolitica: subversion of adaptive immunity and implications for vaccine development.

Authors:  Stella E Autenrieth; Ingo B Autenrieth
Journal:  Int J Med Microbiol       Date:  2007-08-16       Impact factor: 3.473

Review 9.  Current challenges in the development of vaccines for pneumonic plague.

Authors:  Stephen T Smiley
Journal:  Expert Rev Vaccines       Date:  2008-03       Impact factor: 5.217

10.  Yersinia pestis endowed with increased cytotoxicity is avirulent in a bubonic plague model and induces rapid protection against pneumonic plague.

Authors:  Ayelet Zauberman; Avital Tidhar; Yinon Levy; Erez Bar-Haim; Gideon Halperin; Yehuda Flashner; Sara Cohen; Avigdor Shafferman; Emanuelle Mamroud
Journal:  PLoS One       Date:  2009-06-16       Impact factor: 3.240

View more
  19 in total

1.  Yersinia pestis Pla Protein Thwarts T Cell Defense against Plague.

Authors:  Stephen T Smiley; Frank M Szaba; Lawrence W Kummer; Debra K Duso; Jr-Shiuan Lin
Journal:  Infect Immun       Date:  2019-04-23       Impact factor: 3.441

Review 2.  For the Greater (Bacterial) Good: Heterogeneous Expression of Energetically Costly Virulence Factors.

Authors:  Kimberly M Davis
Journal:  Infect Immun       Date:  2020-06-22       Impact factor: 3.441

3.  Effector CD8+ T cells are generated in response to an immunodominant epitope in type III effector YopE during primary Yersinia pseudotuberculosis infection.

Authors:  Yue Zhang; Patricio Mena; Galina Romanov; James B Bliska
Journal:  Infect Immun       Date:  2014-05-05       Impact factor: 3.441

4.  CD8(+) T cells specific to a single Yersinia pseudotuberculosis epitope restrict bacterial replication in the liver but fail to provide sterilizing immunity.

Authors:  Haiqian Shen; Norberto Gonzalez-Juarbe; Krystle Blanchette; Gregory Crimmins; Molly A Bergman; Ralph R Isberg; Carlos J Orihuela; Peter H Dube
Journal:  Infect Genet Evol       Date:  2016-06-04       Impact factor: 3.342

Review 5.  Yersinia versus host immunity: how a pathogen evades or triggers a protective response.

Authors:  Lawton K Chung; James B Bliska
Journal:  Curr Opin Microbiol       Date:  2015-11-27       Impact factor: 7.934

6.  Microbiota-Dependent Sequelae of Acute Infection Compromise Tissue-Specific Immunity.

Authors:  Denise Morais da Fonseca; Timothy W Hand; Seong-Ji Han; Michael Y Gerner; Arielle Glatman Zaretsky; Allyson L Byrd; Oliver J Harrison; Alexandra M Ortiz; Mariam Quinones; Giorgio Trinchieri; Jason M Brenchley; Igor E Brodsky; Ronald N Germain; Gwendalyn J Randolph; Yasmine Belkaid
Journal:  Cell       Date:  2015-10-08       Impact factor: 41.582

7.  Precursor Abundance Influences Divergent Antigen-Specific CD8+ T Cell Responses after Yersinia pseudotuberculosis Foodborne Infection.

Authors:  Yue Zhang; Zhijuan Qiu; Brian S Sheridan; James B Bliska
Journal:  Infect Immun       Date:  2021-07-15       Impact factor: 3.441

8.  CCR2+ Inflammatory Monocytes Are Recruited to Yersinia pseudotuberculosis Pyogranulomas and Dictate Adaptive Responses at the Expense of Innate Immunity during Oral Infection.

Authors:  Yue Zhang; Camille Khairallah; Brian S Sheridan; Adrianus W M van der Velden; James B Bliska
Journal:  Infect Immun       Date:  2018-02-20       Impact factor: 3.609

9.  CCR2+ Inflammatory Dendritic Cells and Translocation of Antigen by Type III Secretion Are Required for the Exceptionally Large CD8+ T Cell Response to the Protective YopE69-77 Epitope during Yersinia Infection.

Authors:  Yue Zhang; Jason W Tam; Patricio Mena; Adrianus W M van der Velden; James B Bliska
Journal:  PLoS Pathog       Date:  2015-10-15       Impact factor: 6.823

10.  Protective immunity against lethal F. tularensis holarctica LVS provided by vaccination with selected novel CD8+ T cell epitopes.

Authors:  Shahar Rotem; Ofer Cohen; Erez Bar-Haim; Liat Bar-On; Sharon Ehrlich; Avigdor Shafferman
Journal:  PLoS One       Date:  2014-01-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.